Cargando…
NFATC2 is a novel therapeutic target for colorectal cancer stem cells
BACKGROUND: Colorectal cancer stem cells (CRC-SCs) contribute to the initiation and progression of colorectal cancer (CRC). However, the underlying mechanisms for the propagation of CRC-SCs have remained elusive. PURPOSE: The objective of this study was to study the role of NFATC2 in maintenance of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199214/ https://www.ncbi.nlm.nih.gov/pubmed/30410349 http://dx.doi.org/10.2147/OTT.S169129 |
_version_ | 1783365094823952384 |
---|---|
author | Lang, Tingyuan Ding, Xiaojuan Kong, Liangsheng Zhou, Xiaoyan Zhang, Zhiqi Ju, Huangxian Ding, Shijia |
author_facet | Lang, Tingyuan Ding, Xiaojuan Kong, Liangsheng Zhou, Xiaoyan Zhang, Zhiqi Ju, Huangxian Ding, Shijia |
author_sort | Lang, Tingyuan |
collection | PubMed |
description | BACKGROUND: Colorectal cancer stem cells (CRC-SCs) contribute to the initiation and progression of colorectal cancer (CRC). However, the underlying mechanisms for the propagation of CRC-SCs have remained elusive. PURPOSE: The objective of this study was to study the role of NFATC2 in maintenance of the stemness in CRC-SCs. METHOD: The expression levels of mRNA and protein were determined by qRT-PCR and western-blot, respectively. CRC-SCs were isolated by spheroid formation assay and flowcytometry. The sphere-forming and self-renewal abilities of CRC-SCs were determined by spheroid formation assay. The tumorigenicity of CRC-SCs was determined by cell-derived xenograft model. Gene manipulation was performed by lentivirus-mediated delivery system. RESULTS: We first found that NFATC2 is upregulated in primary CRC-SCs. Overexpression of NFATC2 promotes self-renewal and the expression of stem cell markers of CRC-SCs. Conversely, knockdown of NFATC2 attenuates stem cell-like properties of CRC-SCs. Mechanistic analysis indicated that NFATC2 upregulates the expression of AJUBA, downregulates the phosphorylation level of YAP, and therefore activates the transcriptional activities of YAP and promotes the stemness of CRC-SCs. CONCLUSION: Our findings demonstrate NFATC2 as an oncogene that can promote the stemness of CRC-SCs. This work suggests a novel therapeutic strategy against CRC caused by aberrant expression of NFATC2. |
format | Online Article Text |
id | pubmed-6199214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61992142018-11-08 NFATC2 is a novel therapeutic target for colorectal cancer stem cells Lang, Tingyuan Ding, Xiaojuan Kong, Liangsheng Zhou, Xiaoyan Zhang, Zhiqi Ju, Huangxian Ding, Shijia Onco Targets Ther Original Research BACKGROUND: Colorectal cancer stem cells (CRC-SCs) contribute to the initiation and progression of colorectal cancer (CRC). However, the underlying mechanisms for the propagation of CRC-SCs have remained elusive. PURPOSE: The objective of this study was to study the role of NFATC2 in maintenance of the stemness in CRC-SCs. METHOD: The expression levels of mRNA and protein were determined by qRT-PCR and western-blot, respectively. CRC-SCs were isolated by spheroid formation assay and flowcytometry. The sphere-forming and self-renewal abilities of CRC-SCs were determined by spheroid formation assay. The tumorigenicity of CRC-SCs was determined by cell-derived xenograft model. Gene manipulation was performed by lentivirus-mediated delivery system. RESULTS: We first found that NFATC2 is upregulated in primary CRC-SCs. Overexpression of NFATC2 promotes self-renewal and the expression of stem cell markers of CRC-SCs. Conversely, knockdown of NFATC2 attenuates stem cell-like properties of CRC-SCs. Mechanistic analysis indicated that NFATC2 upregulates the expression of AJUBA, downregulates the phosphorylation level of YAP, and therefore activates the transcriptional activities of YAP and promotes the stemness of CRC-SCs. CONCLUSION: Our findings demonstrate NFATC2 as an oncogene that can promote the stemness of CRC-SCs. This work suggests a novel therapeutic strategy against CRC caused by aberrant expression of NFATC2. Dove Medical Press 2018-10-15 /pmc/articles/PMC6199214/ /pubmed/30410349 http://dx.doi.org/10.2147/OTT.S169129 Text en © 2018 Lang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Lang, Tingyuan Ding, Xiaojuan Kong, Liangsheng Zhou, Xiaoyan Zhang, Zhiqi Ju, Huangxian Ding, Shijia NFATC2 is a novel therapeutic target for colorectal cancer stem cells |
title | NFATC2 is a novel therapeutic target for colorectal cancer stem cells |
title_full | NFATC2 is a novel therapeutic target for colorectal cancer stem cells |
title_fullStr | NFATC2 is a novel therapeutic target for colorectal cancer stem cells |
title_full_unstemmed | NFATC2 is a novel therapeutic target for colorectal cancer stem cells |
title_short | NFATC2 is a novel therapeutic target for colorectal cancer stem cells |
title_sort | nfatc2 is a novel therapeutic target for colorectal cancer stem cells |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199214/ https://www.ncbi.nlm.nih.gov/pubmed/30410349 http://dx.doi.org/10.2147/OTT.S169129 |
work_keys_str_mv | AT langtingyuan nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells AT dingxiaojuan nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells AT kongliangsheng nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells AT zhouxiaoyan nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells AT zhangzhiqi nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells AT juhuangxian nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells AT dingshijia nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells |